Pyxis Oncology’s (PYXS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a $5.00 price target on the stock. HC Wainwright also issued estimates for Pyxis Oncology’s Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.34) EPS, FY2026 earnings at ($1.25) EPS, FY2027 earnings at ($1.17) EPS, FY2028 earnings at ($0.53) EPS and FY2029 earnings at $0.24 EPS.

A number of other research firms have also recently weighed in on PYXS. William Blair cut shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday, November 21st. Royal Bank of Canada restated an “outperform” rating and issued a $8.00 price target (down previously from $10.00) on shares of Pyxis Oncology in a research note on Friday, December 20th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Pyxis Oncology presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.20.

Pyxis Oncology Stock Up 8.0 %

Shares of NASDAQ PYXS opened at $1.21 on Wednesday. The firm’s 50-day moving average price is $1.33 and its two-hundred day moving average price is $2.36. Pyxis Oncology has a 52-week low of $0.99 and a 52-week high of $6.18. The stock has a market capitalization of $74.52 million, a P/E ratio of -1.17 and a beta of 1.11.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.01. The company had revenue of $16.15 million during the quarter. As a group, equities research analysts expect that Pyxis Oncology will post -1.04 earnings per share for the current year.

Institutional Trading of Pyxis Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. LMR Partners LLP acquired a new position in shares of Pyxis Oncology during the third quarter valued at approximately $294,000. Intech Investment Management LLC acquired a new position in shares of Pyxis Oncology during the 3rd quarter valued at $55,000. MetLife Investment Management LLC raised its stake in shares of Pyxis Oncology by 41.1% in the 3rd quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after buying an additional 5,484 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Pyxis Oncology in the third quarter valued at $1,405,000. Finally, State Street Corp lifted its holdings in shares of Pyxis Oncology by 28.0% in the third quarter. State Street Corp now owns 951,251 shares of the company’s stock valued at $3,491,000 after buying an additional 208,344 shares during the period. 39.09% of the stock is currently owned by institutional investors.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.